COVID-19 Significantly Impacted Health Services for Patients with Pancreatic Cancer
Drug Topics
NOVEMBER 18, 2024
Researchers analyzed the impact of the COVID-19 pandemic on outcomes for patients with pancreatic cancer living in England.
Mon.Nov 18, 2024
281 
Sanofi lays out €40M to beef up transplant, diabetes drug production in France
Fierce Pharma
NOVEMBER 18, 2024
With several high-profile manufacturing outlays already in the books in Europe this year, Sanofi is returning to the bloc in a bid to boost production for a long-approved transplant treatment and a | Sanofi has unveiled a 40 million euro investment at its Lyon Gerland biomanufacturing site in France. The cash infusion will help bolster local production of the company’s polyclonal antibody Thymoglubulin for kidney transplant rejection, as well as expected future capacity needs for the type 1 diab
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
How Manufacturing Disruptions, Price Competition Contribute to Drug Shortages
Drug Topics
NOVEMBER 18, 2024
Michael Ganio, PharmD, BCPS, FASHP, discusses how the industry can become more resilient.
The first MASH drug could open the door for others — including GLP-1s
PharmaVoice
NOVEMBER 18, 2024
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Self-Management Behavioral Interventions May Improve Pain Outcomes in HIV
Drug Topics
NOVEMBER 18, 2024
Researchers evaluated the efficacy of a self-managed intervention vs enhanced usual care.
Antibacterial peptides instrumental in efficiency against resistant bacteria
Pharmafile
NOVEMBER 18, 2024
This month, the Chalmers University of Technology in Sweden have published the results of a study demonstrating that resistant bacteria, when paired with material equipped with antibacterial peptides, can regain susceptibility to antibiotics. The study, conducted in a laboratory environment, concluded that antibiotics – such as oxacillin – could achieve an increase in their bactericidal […] The post Antibacterial peptides instrumental in efficiency against resistant bacteria appeared first
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
FDA Grants Rare Pediatric Disease Designation for Treatment of Neonatal SP-B Deficiency
Pharmacy Times
NOVEMBER 18, 2024
The disorder presents as severe lung disease, with lung transplantation as the only current therapeutic option for long-term survival.
Maintenance Use of ADHD Therapies May Be Safe in Pregnancy
Drug Topics
NOVEMBER 18, 2024
Continued methylphenidate or atomoxetine use may be safe, but additional studies are needed.
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
PharmaVoice
NOVEMBER 18, 2024
Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.
Q&A: Rite Aid Pharmacist Boosts Public Health Through Immunization and Clinical Programs
Drug Topics
NOVEMBER 18, 2024
Drug Topics sat down with Adam J. James, PharmD, to discuss his journey from chain pharmacist to innovation leader at Rite Aid.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
CHMP Recommends Lazertinib With Amivantamab to Treat EGFR-Mutated Advanced NSCLC
Pharmacy Times
NOVEMBER 18, 2024
Lazertinib in combination with amivantamab displays positive outcomes for non–small cell lung cancer compared with standard first line treatment.
Tips for Educating Patients About Lifestyle Modifications to Manage Diabetes
Drug Topics
NOVEMBER 18, 2024
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, also discusses ways community pharmacists can collaborate with other healthcare professionals to enhance diabetes management.
Smart ring maker Oura picks up $75M series D, inks strategic partnership with Dexcom
Fierce Healthcare
NOVEMBER 18, 2024
Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring, which tracks sleep, heart rate and activity. | Oura is partnering with medical device maker Dexcom to integrate data from glucose biosensors with the Oura Ring.
Empowering Veterans: How the VALOR-QI Program Lowers Atherosclerotic Cardiovascular Disease Risk
Pharmacy Times
NOVEMBER 18, 2024
Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
CVS, Glenview Capital reach deal that adds 4 board members
Fierce Healthcare
NOVEMBER 18, 2024
As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors. | As CVS Health pushes to turn around its financial fortunes, it has entered into a deal with key investor Glenview Capital Management that will add four members to its board of directors.
Study Identifies Factors Influencing Quality of Life for Young Breast Cancer Survivors
Pharmacy Times
NOVEMBER 18, 2024
Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.
STAT+: AHA 2024: First, a call for prevention. Then a spotlight on obesity drugs
STAT
NOVEMBER 18, 2024
CHICAGO — This year’s scientific sessions on the latest research in cardiovascular disease began not with the buzzy new obesity drugs but with a sobering look at progress stalling or even reversing in common chronic illnesses. The overture to the American Heart Association’s conference, coming as the organization celebrates its 100th year, began with Valentin Fuster of Mount Sinai Hospital lamenting the predicted shift in overall cardiovascular disease burden, worsenin
Are Nonhallucinogenic Psychedelics a Pharmacy Oxymoron?
Pharmacy Times
NOVEMBER 18, 2024
The pipeline of hallucinogenic and nonhallucinogenic psychedelic medicines Is exploding.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Despite fears over RFK Jr. pick, industry should focus more on FDA job: analyst
Fierce Pharma
NOVEMBER 18, 2024
Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the boat as much as feared for the biopharma industry.
AHA 2024: Email Reminders Improve Flu Shot Rates, Particularly Among Heart Attack Survivors
Pharmacy Times
NOVEMBER 18, 2024
The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.
Neurogene falls again on Rett gene therapy side effects
pharmaphorum
NOVEMBER 18, 2024
Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares
AbbVie’s Elahere wins European approval for certain ovarian cancers
Pharmaceutical Technology
NOVEMBER 18, 2024
The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.
AI could 'cut ECG result wait times and speed up treatment'
pharmaphorum
NOVEMBER 18, 2024
Using AI-powered PanEcho software for screening ECGs could deliver results more quickly and allow treatment to be started earlier.
How RFK Jr. could upend decades of policy on vaccines
STAT
NOVEMBER 18, 2024
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. It’s been a busy November here at STAT, and it ain’t slowing down. I’m writing this on Friday afternoon and everyone’s on Zoom, discussing new coverage ideas. I guess I’m a bit biased, but I think we’ve been doing incredible work covering the election and its consequences.
Grifols linked to €7bn takeover offer from Brookfield
pharmaphorum
NOVEMBER 18, 2024
Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company.A report in Spanish newspaper El Confidencial suggests that Brookfield is preparing to make a bid to take a 65% controlling stake in the drugmaker for €10.50 per share, worth around €7 billion ($7.4 billion).
Switching from Adderall to Vyvanse: Why and how to do it safely
The Checkup by Singlecare
NOVEMBER 18, 2024
Left untreated, attention deficit hyperactivity disorder ( ADHD ) can negatively impact relationships and school and work performance. Fortunately, there are several ADHD treatment options available. Stimulants such as Adderall , Vyvanse , Ritalin , and Concerta are commonly prescribed to increase focus and attention while boosting impulse control. Adderall ( amphetamine-dextroamphetamine ) and Vyvanse ( lisdexamfetamine dimesylate ) are both brand-name central nervous system (CNS) stimulants a
Syndax gets FDA okay for first-in-class leukaemia drug
pharmaphorum
NOVEMBER 18, 2024
Shortly after a disappointing trial readout for Syndax's menin inhibitor Revuforj in one form of leukaemia, the company has claimed FDA approval in another
AHA 2024: Plozasiran demonstrates promising Phase III results in FCS adults
Pharmaceutical Technology
NOVEMBER 18, 2024
During AHA 2024, data were presented from the Phase III trial of plozasiran targeting adults with genetically or clinically diagnosed FCS,
AbbVie bags EU nod for key drug from ImmunoGen takeover
pharmaphorum
NOVEMBER 18, 2024
AbbVie's Elahere is approved in EU, ending a 10-year wait for a new therapy for platinum-resistant ovarian cancer.
Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases
Pharmaceutical Technology
NOVEMBER 18, 2024
The EC has granted marketing authorisation for Sandoz's Afqlir for the treatment of various retinal diseases.
Amid Seattle downsizing, Gilead cuts 100+ positions at California HQ
Fierce Pharma
NOVEMBER 18, 2024
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. | The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters.
FDA approves Syndax’s Revuforj to treat leukaemia
Pharmaceutical Technology
NOVEMBER 18, 2024
The US FDA has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating acute leukaemia with KMT2A translocation.
Interprofessional Education in Medical School Creates a Collaborative Environment
Pharmacy Times
NOVEMBER 18, 2024
Adaptability, teamwork, and a culture of lifetime learning are required virtues in our rapidly evolving medical landscape.
Let's personalize your content